个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Jianming Xu[1,*1] ; Lin Shen[2] ; Zhiwei Zhou[3] ; Jie Li[2] ; Chunmei Bai[4] ; Yihebali Chi[5] ; Zhiping Li[6] ; Nong Xu[7] ; Enxiao Li[8] ; Tianshu Liu[9] ; Yuxian Bai[10] ; Ying Yuan[11] ; Xingya Li[12] ; Xiuwen Wang[13] ; Jia Chen[14] ; Jieer Ying[15] ; Xianjun Yu[16] ; Shukui Qin[17] ; Xianglin Yuan[18] ; Tao Zhang[19] ; Yanhong Deng[20] ; Dianrong Xiu[21] ; Ying Cheng[22] ; Min Tao[23] ; Ru Jia[1] ; Wei Wang[3] ; Jing Li[24] ; Songhua Fan[24] ; Mengye Peng[24] ; Weiguo Su[24] ;
机构： [1]Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China [2]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China [3]Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China [4]Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China [5]National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [6]Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China [7]Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China [8]Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China [9]Department of Medical Oncology, Zhongshan Hospital of Fudan University, Shanghai, China [10]Department of Gastrointestinal [11]Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [12]Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [13]Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China [14]Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China [15]Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, China [16]Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China [17]People’s Liberation Army Cancer Center of Nanjing Jinling Hospital, Nanjing, China [18]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [19]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [20]Department of Medical Oncology, The Sixth Affiliated Hospital, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases l, Sun Yat-sen University, Guangzhou, Guangdong, China [21]Department of General Surgery, Peking University Third Hospital, Beijing, China [22]Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China [23]Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China [24]Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China
出处：
DOI： 10.1016/S1470-2045(20)30496-4
ISSN：

摘要：
Background: Therapeutic options for advanced neuroendocrine tumours (NETs) are limited. We investigated the efficacy and safety of surufatinib (HMPL-012, sulfatinib) in patients with extrapancreatic NETs. Methods: SANET-ep was a randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 24 hospitals across China. Patients (aged 18 years or older) with unresectable or metastatic, well differentiated, extrapancreatic NETs, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and progression on no more than two types of previous systemic regimens were enrolled. Patients were centrally randomly assigned (2:1) using stratified block randomisation (block size 3) via an interactive web response system to receive oral surufatinib at 300 mg per day or matching placebo. Randomisation was stratified by tumour origin, pathological grade, and previous treatment. Patients, investigators, research staff and the sponsor study team were masked to treatment allocation. Crossover to the surufatinib group was allowed for patients in the placebo group at disease progression. The primary endpoint was investigator-assessed progression-free survival, which was analysed in the intention-to-treat population. A preplanned interim analysis was done at 70% of predicted progression-free survival events. This study was registered with ClinicalTrials.gov, NCT02588170. Follow-up is ongoing. Findings: Between Dec 9, 2015, and March 31, 2019, 198 patients were randomly assigned to surufatinib (n=129) or placebo (n=69). Median follow-up was 13·8 months (95% CI 11·1–16·7) in the surufatinib group and 16·6 months (9·2–not calculable) in the placebo group. Investigator-assessed median progression-free survival was 9·2 months (95% CI 7·4–11·1) in the surufatinib group versus 3·8 months (3·7–5·7) in the placebo group (hazard ratio 0·33; 95% CI 0·22–0·50; p<0·0001). As the trial met the predefined criteria for early discontinuation of the study at the interim analysis, the study was terminated early, as recommended by the independent data monitoring committee. The most common treatment-related adverse events of grade 3 or worse were hypertension (47 [36%] of 129 patients in the surufatinib group vs nine [13%] of 68 patients in the placebo group) and proteinuria (25 [19%] vs zero). Treatment-related serious adverse events were reported in 32 (25%) of 129 patients in the surufatinib group and nine (13%) of 68 patients in the placebo group. Treatment-related deaths occurred in three patients in the surufatinib group (disseminated intravascular coagulation and hepatic encephalopathy, liver injury, and death with unknown reason) and one patient in the placebo group (cachexia and respiratory failure). Interpretation: Progression-free survival was significantly longer in patients given surufatinib compared with patients given placebo, and surufatinib has a favourable benefit-to-risk profile in patients with progressive, advanced, well differentiated extrapancreatic NETs. Our results suggest that surufatinib might be a new treatment option for this population. Funding: Hutchison MediPharma. © 2020 Elsevier Ltd

基金：
This study was funded by Hutchison MediPharma. Medical writing support, funded by Hutchison MediPharma, was provided by Kristen Perry (Nucleus Global, Shanghai, China). We thank the patients, their families, the investigators, and the teams who participated in this trial; and Haesun Choi (MD Anderson Cancer Center, Houston, TX, USA) and Marianne Pavel (Friedrich-Alexander-University of Erlangen- Nürnberg, Germany) for the post-hoc independent image adjudication.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2020]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China [*1]Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China [*1]Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China
推荐引用方式(GB/T 7714)：
Jianming Xu,Lin Shen,Zhiwei Zhou,et al.Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study[J].LANCET ONCOLOGY.2020,21(11):1500-1512.doi:10.1016/S1470-2045(20)30496-4.
APA：
Jianming Xu,Lin Shen,Zhiwei Zhou,Jie Li,Chunmei Bai...&Weiguo Su.(2020).Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.LANCET ONCOLOGY,21,(11)
MLA：
Jianming Xu,et al."Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study".LANCET ONCOLOGY 21..11(2020):1500-1512

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号